KR950014073A - 이소퀴놀린 - Google Patents

이소퀴놀린 Download PDF

Info

Publication number
KR950014073A
KR950014073A KR1019940028732A KR19940028732A KR950014073A KR 950014073 A KR950014073 A KR 950014073A KR 1019940028732 A KR1019940028732 A KR 1019940028732A KR 19940028732 A KR19940028732 A KR 19940028732A KR 950014073 A KR950014073 A KR 950014073A
Authority
KR
South Korea
Prior art keywords
compound
formula
ester
acid addition
salt
Prior art date
Application number
KR1019940028732A
Other languages
English (en)
Inventor
나에프 레토
Original Assignee
페터 래스, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페터 래스, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 페터 래스, 한스 루돌프 하우스
Publication of KR950014073A publication Critical patent/KR950014073A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 하기하는 일반식(I)의 화합물, 이의 생리적으로-가수분해가능한 및-허용가능한 에스테르 및 염에 관한 것이다. 상기 화합물, 에스테르 및 제약적으로 허용가능한 산 부가염은, 예를들어 천식 치료용의 의약품으로 유용하다.
R은 상기 정의한 바와 동일하다.

Description

이소퀴놀린
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식( I )의 화합물, 또는 이의 생리적으로 -가수분해가능한 및-허용가능한 에스테르 또는 상기 화합물 또는 에스테르의 산 부가염 :
    상기 식에서, R은 에틸 또는 n-프로필이다.
  2. 제1항에 있어서, R이 에틸인 일반식(I)이 화합물 또는 이의 산 부가염.
  3. 제1항에 있어서, R이 n-프로필인 일반식(I)의 화합물 또는 이의 산 부가염.
  4. 제약학적으로 허용가능한 회석제 또는 그것을 위한 담체와 함께 제1항 내지 제3항중 어느 한 항에서 정의한 일반식(Ⅰ)의 화합물, 또는 이의 생리적으로 -가수분해가능한 및-허용가능한 에스테르 또는 상기 화합물 또는 에스테르의 제약학적으로 허용가능한 산 부가염을 포함하는 제약학적 조성물.
  5. 제1항 내지 제3항중 어느 한 항에 있어서, 의약품으로 사용하기 위한, 일반식(I)의 화합물, 또는 이의 생리적으로 -가수분해가능한 및-허용가능한 에스테르, 또는 상기 화합물 또는 에스테르의 제약학적으로 허용가능한 산 부가염.
  6. 제5항에 있어서, 수축성 또는 염증성 기도 질병의 치료에 사용하기 위한 화합물, 에스테르 또는 염.
  7. 제6항에 있어서, 천식의 치료에 사용하기 위한 화합물, 에스테르 또는 염.
  8. a)하기 일반식(Ⅱ)의 화합물을 탈보호 및/또는 탈수소화시켜 하기 일반식(I)의 화합물을 제조하며, b)하기 일반식(I)의 화합물을 에스테르화시켜 하기 일반식(I)의 화합물의 생리적으로 -가수분해 가능한 및-허용가능한 에스테르를 제조하고, 상기 단계 a) 또는 b)의 생성물을 유리형태 또는 산부가염 형태로 회수하는 단계를 포함하여, 제1항에서 정의한 하기 일반식(I)의 화합물, 에스테르 또는 염을 제조하는 방법 :
    상기식에서, R은 제1항에서 정의한 바와 같고 : X는 수소이고, R1과 R2는 점선으로 표시한 추가의 결합을 나타내거나 : X는 히드록시 보호기이고, Rl과 R2는 각각 수고 또는 점선으로 표시한 추가이 결합을 나타낸다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940028732A 1993-11-05 1994-11-03 이소퀴놀린 KR950014073A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939322828A GB9322828D0 (en) 1993-11-05 1993-11-05 Organic compounds
GB9322828.6 1993-11-05

Publications (1)

Publication Number Publication Date
KR950014073A true KR950014073A (ko) 1995-06-15

Family

ID=10744697

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940028732A KR950014073A (ko) 1993-11-05 1994-11-03 이소퀴놀린

Country Status (26)

Country Link
US (1) US5747506A (ko)
EP (1) EP0664289A3 (ko)
JP (1) JPH07188176A (ko)
KR (1) KR950014073A (ko)
CN (1) CN1051998C (ko)
AT (1) AT404940B (ko)
AU (1) AU685852B2 (ko)
CA (1) CA2135000A1 (ko)
CH (1) CH688478A5 (ko)
CZ (1) CZ282329B6 (ko)
DE (1) DE4438737A1 (ko)
FI (1) FI945191A (ko)
FR (1) FR2711989B1 (ko)
GB (2) GB9322828D0 (ko)
HK (1) HK1005776A1 (ko)
HU (1) HU217120B (ko)
IL (1) IL111518A (ko)
IT (1) IT1273993B (ko)
NO (1) NO302293B1 (ko)
NZ (1) NZ264851A (ko)
PE (1) PE30395A1 (ko)
PL (1) PL178210B1 (ko)
RU (1) RU2144027C1 (ko)
SK (1) SK280298B6 (ko)
TW (1) TW353067B (ko)
ZA (1) ZA948738B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
ID19155A (id) * 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
US5919794A (en) * 1998-05-11 1999-07-06 Virginia Commonwealth University Methods of using pharmaceutical tetrahydroisoquinolines
US6200771B1 (en) * 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
DE19930614A1 (de) * 1999-07-02 2001-01-04 Mann & Hummel Filter Filtereinsatz
CA2381802C (en) 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of roflumilast and salmeterol
JP2003526677A (ja) * 2000-03-14 2003-09-09 ザ・ユニバーシテイ・オブ・ウエスタン・オンタリオ 骨形成に影響を与える組成物および方法
AU2002224835A1 (en) * 2000-11-14 2002-05-27 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Dihydroisoquinolines as novel phosphodiesterase inhibitors
NZ525147A (en) 2000-11-14 2004-10-29 Altana Pharma Ag (Dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
DE10229762A1 (de) * 2002-07-03 2004-01-22 Aventis Pharma Deutschland Gmbh Pyrazoloisoquinolinenderivaten zur Inhibierung von NFkappaB-induzierende Kinase
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
US7795385B2 (en) * 2004-12-17 2010-09-14 Bexar Global, Inc. Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
PL2366699T3 (pl) * 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
JP6265583B2 (ja) 2008-10-17 2018-01-24 ウィスコンシン アルムニ リサーチ ファンデイション 生理活性アルファベータペプチドを作製する方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0067711A2 (en) * 1981-06-16 1982-12-22 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. New 1-benzyl-3,4-dihydro-isoquinoline derivative
KR830003429A (ko) * 1980-08-08 1983-06-20 부자 앙드레 신규 이소퀴놀린 유도체의 제법
US4785104A (en) * 1986-05-21 1988-11-15 Egis Gyogyszergyar 3-(hydroxymethyl)-isoquinoline derivatives
JPH01213267A (ja) * 1988-01-08 1989-08-28 Sandoz Ag イソキノリン誘導体、その製法および用途
JPH04275276A (ja) * 1990-12-13 1992-09-30 Sandoz Ag 新規ジヒドロイソキノリン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB645139A (en) * 1946-10-22 1950-10-25 Servita Gyogyszeryar Es Vegyip Improved process for the production of isoquinoline derivatives
GB1400425A (en) * 1971-09-22 1975-07-16 Rolland Sa A Substituted 3-hydroxymethyl-isoquinolines and derivatives
US3878215A (en) * 1971-12-01 1975-04-15 Sandoz Ag 2-Alkyl-3-substituted-4-aryl isoquinolines
US4018927A (en) * 1973-12-17 1977-04-19 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with papaverine alkaloids
DE3244594A1 (de) * 1982-12-02 1984-06-07 Hoechst Ag, 6230 Frankfurt 1-phenylisochinolinderivate und verfahren zu ihrer herstellung, diese verbindung enthaltende pharmazeutische praeparate und deren anwendung
GB8328052D0 (en) * 1983-10-20 1983-11-23 Beecham Group Plc Compounds
US4761403A (en) * 1986-04-09 1988-08-02 Abbott Laboratories Lipoxygenase inhibiting compounds
CA1330560C (en) * 1986-05-21 1994-07-05 Maurits E. A. Vandewalle Di- and tetrahydroisoquinoline derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830003429A (ko) * 1980-08-08 1983-06-20 부자 앙드레 신규 이소퀴놀린 유도체의 제법
EP0067711A2 (en) * 1981-06-16 1982-12-22 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. New 1-benzyl-3,4-dihydro-isoquinoline derivative
US4785104A (en) * 1986-05-21 1988-11-15 Egis Gyogyszergyar 3-(hydroxymethyl)-isoquinoline derivatives
JPH01213267A (ja) * 1988-01-08 1989-08-28 Sandoz Ag イソキノリン誘導体、その製法および用途
JPH04275276A (ja) * 1990-12-13 1992-09-30 Sandoz Ag 新規ジヒドロイソキノリン誘導体

Also Published As

Publication number Publication date
NZ264851A (en) 1996-04-26
EP0664289A2 (en) 1995-07-26
GB2283488B (en) 1997-12-03
ITRM940706A1 (it) 1996-05-03
ATA204894A (de) 1998-08-15
FI945191A0 (fi) 1994-11-03
ITRM940706A0 (it) 1994-11-03
GB9322828D0 (en) 1993-12-22
RU2144027C1 (ru) 2000-01-10
IL111518A0 (en) 1995-01-24
GB9421985D0 (en) 1994-12-21
GB2283488A (en) 1995-05-10
PL305705A1 (en) 1995-05-15
CZ269894A3 (en) 1995-07-12
HU9403184D0 (en) 1994-12-28
AU7761094A (en) 1995-05-18
NO944187L (no) 1995-05-08
FI945191A (fi) 1995-05-06
ZA948738B (en) 1996-05-06
NO944187D0 (no) 1994-11-03
CZ282329B6 (cs) 1997-06-11
CN1106801A (zh) 1995-08-16
IT1273993B (it) 1997-07-14
CA2135000A1 (en) 1995-05-06
DE4438737A1 (de) 1995-05-11
US5747506A (en) 1998-05-05
CN1051998C (zh) 2000-05-03
FR2711989B1 (fr) 1996-06-14
SK131994A3 (en) 1995-06-07
EP0664289A3 (en) 1995-09-13
RU94040170A (ru) 1996-10-10
AU685852B2 (en) 1998-01-29
HUT71350A (en) 1995-11-28
SK280298B6 (sk) 1999-11-08
PE30395A1 (es) 1995-10-25
IL111518A (en) 1999-06-20
PL178210B1 (pl) 2000-03-31
HK1005776A1 (en) 1999-01-22
AT404940B (de) 1999-03-25
TW353067B (en) 1999-02-21
NO302293B1 (no) 1998-02-16
HU217120B (hu) 1999-11-29
FR2711989A1 (fr) 1995-05-12
JPH07188176A (ja) 1995-07-25
CH688478A5 (de) 1997-10-15

Similar Documents

Publication Publication Date Title
KR950014073A (ko) 이소퀴놀린
CA2216623A1 (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
MD1233B1 (en) Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
KR960000230A (ko) 간담즙성 질병 치료제
ATE130604T1 (de) Neue arylethylaminderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
FI884626A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen 4H-1-bentsopyran-4-onijohdoksen tai sen suolan valmistamiseksi ja menetelmässä käyttökelpoinen välituote
KR860006452A (ko) 피페리딘 화합물의 제조 방법
EP0393494A3 (en) Bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
KR910014395A (ko) 신규 화합물
KR900018048A (ko) 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌
KR880001677A (ko) β-락탐 화합물, 그의 제조 방법, 이를 함유하는 세균 감염성 질병 치료용 약제 및 그의 합성을 위한 중간체
KR890001965A (ko) 스퍼구알린 관련 유도체
KR960022498A (ko) 에스큘레틴 유도체, 그의 제조방법 및 약학조성물
KR940007001A (ko) 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
KR900009677A (ko) 신규 화합물들
KR880000432A (ko) 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체
HUP9802096A2 (hu) Piperidino-alkanol-vegyületeket tartalmazó orális adagolású oldat formájú gyógyszerkészítmény, és eljárás előállítására
NL179059C (nl) Werkwijze ter bereiding van een geneesmiddel met ontstekingsremmende werking, gevormd geneesmiddel en werkwijze ter bereiding van geneeskrachtige verbindingen, geschikt voor gebruik bij deze werkwijze.
GB1497266A (en) Aryloxy-and arylthio-alkanoates having cholesterol-reducing properties
KR850008491A (ko) 신규 세팔로스포린의 제조방법
KR920002594A (ko) 5-이소티아졸아민 유도체
ATE34739T1 (de) Neue 2-pyridin-thiol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
KR920008035A (ko) 타이로신 유도체 및 그 제조방법
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
KR850700244A (ko) 세팔로스포린 유도체 및 그 염의 제조방법

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application